Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA
Yutaka Matsuyama. Measuring PROs for people with Parkinson’s in clinical trials. Takeda Expert Conference on Parkinson’s Disease. Tokyo. 2020/12/12.
Hagiwara Y. Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models. PeSeTo International Symposium on Public Health 2016, Tokyo, Japan, March 15, 2016.
Shinozaki T, Matsuyama Y. (November 2014). “Doubly robust estimation of a marginal structural model in the exposed population.” At: Kyoto International Conference on Modern Statistics in the 21st Century, Kyoto, Japan. Chair: Manabu Iwasaki. (Invited)
Matsuyama Y. Semiparametric estimation of treatment effect in a randomized clinical trial with missing data. International Symposium Incomplete Data Analysis and Causal Inference, Osaka University, 22-23 September 2013.
Matsuyama Y and Tanaka Y. Estimation of treatment effect adjusting for non-compliance using the intensity score method. 科学研究費補助金(基盤研究 (A) (1))シンポジウム「不完全データ解析とその周辺」 東京.2006/1/23.
Shinozaki T, Matsuyama Y. Data analysis on real world data: an overview. In: Sudoh, O. (editor). Epidemiologic Research on Real World Medical Data in Japan. Switzerland: Springer International Publishing, 2019 (forthcoming).
Oba K, Paoletti X. Evaluation of Surrogate Endpoints using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. In: Matsui S, Crowley J(Eds.) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, Singapore, 2017
Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A,Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis. Second Edition, Demos Medical Publishing, NY, 2017